Central regulation of ejaculation and the therapeutic role of serotonergic agents in premature ejaculation
Abstract
Premature ejaculation (PE) is characterized by a short ejaculatory latency time, poor control over ejaculation and a negative impact on quality of life. The process of ejaculation is under central control, and serotonin (5-HT) is a key mediator; therefore, SSRIs and tricyclic antidepressants, including paroxetine, sertraline and clomipramine, are commonly used with chronic daily dosing in the treatment of PE. Dapoxetine, a short-acting SSRI that acts supraspinally to inhibit ejaculation, has been approved in several European countries for on-demand treatment of PE. With a range of centrally acting treatment options, treatment should be tailored to meet the needs and preferences of individual patients.
Read the paper
Related studies
- Improving the translation of search strategies using the Polyglot Search Translator: a randomized controlled trial
- Nutritional, Physical, Cognitive, and Combination Interventions and Frailty Reversal Among Older Adults: A Randomized Controlled Trial
- Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study
- A randomized, controlled trial of oral propranolol in infantile hemangioma
- Clinical phenotypes of delirium during critical illness and severity of subsequent long-term cognitive impairment: a prospective cohort study
- Increased physical activity improves sleep and mood outcomes in inactive people with insomnia: a randomized controlled trial
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.